Tavros Therapeutics
Leading the new frontier of targeted cancer therapies exploiting tumors’ genetic vulnerabilities.
Leading the new frontier of targeted cancer therapies exploiting tumors’ genetic vulnerabilities.
Tavros Therapeutics is a precision oncology platform company founded in 2019 with the slogan "Leading the new frontier of targeted cancer therapies exploiting tumors' genetic vulnerabilities." The company is based in Research Triangle Park, N.C. and is at the forefront of developing targeted therapies by leveraging tumors' genetic vulnerabilities. By utilizing its proprietary platform and map of synthetic lethal relationships, Tavros is building an innovative pipeline of small-molecule drug candidates. The management team, comprised of successful serial entrepreneurs, has extensive expertise in functional genomics, tumor genetics, and drug discovery. Currently, there is no publicly available information regarding their industries, last investment, or associated investors.
There is no investment information
No recent news or press coverage available for Tavros Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
